BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasser Y, Boeckxstaens GE, Wouters MM, Schemann M, Vanner S. Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil 2014;26:455-69. [PMID: 24602069 DOI: 10.1111/nmo.12316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Fritz N, Berens S, Dong Y, Martínez C, Schmitteckert S, Houghton LA, Goebel-Stengel M, Wahl V, Kabisch M, Götze D, D'Amato M, Zheng T, Röth R, Mönnikes H, Tesarz J, Engel F, Gauss A, Raithel M, Andresen V, Keller J, Frieling T, Pehl C, Stein-Thöringer C, Clarke G, Kennedy PJ, Cryan JF, Dinan TG, Quigley EMM, Spiller R, Beltrán C, Madrid AM, Torres V, Mayer EA, Sayuk G, Gazouli M, Karamanolis G, Bustamante M, Estivil X, Rabionet R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Schmidt B, Franke A, Lieb W, Herzog W, Boeckxstaens G, Wouters MM, Simrén M, Rappold GA, Vicario M, Santos J, Schaefert R, Lorenzo-Bermejo J, Niesler B. The serotonin receptor 3E variant is a risk factor for female IBS-D. J Mol Med (Berl) 2022;100:1617-27. [PMID: 36121467 DOI: 10.1007/s00109-022-02244-w] [Reference Citation Analysis]
2 Mohr S, Fritz N, Hammer C, Martínez C, Berens S, Schmitteckert S, Wahl V, Schmidt M, Houghton LA, Goebel-Stengel M, Kabisch M, Götze D, Milovač I, D'Amato M, Zheng T, Röth R, Mönnikes H, Engel F, Gauss A, Tesarz J, Raithel M, Andresen V, Frieling T, Keller J, Pehl C, Stein-Thöringer C, Clarke G, Kennedy PJ, Cryan JF, Dinan TG, Quigley EMM, Spiller R, Beltrán C, Madrid AM, Torres V, Pérez de Arce E, Herzog W, Mayer EA, Sayuk G, Gazouli M, Karamanolis G, Kapur-Pojskič L, Bustamante M, Rabionet R, Estivil X, Franke A, Lieb W, Boeckxstaens G, Wouters MM, Simrén M, Rappold GA, Vicario M, Santos J, Schaefert R, Lorenzo-Bermejo J, Niesler B. The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. J Cell Mol Med 2021;25:8047-61. [PMID: 34165249 DOI: 10.1111/jcmm.16736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cheng L, Luo QQ, Chen SL. The role of intestinal mast cell infiltration in irritable bowel syndrome. J Dig Dis 2021;22:143-51. [PMID: 33511763 DOI: 10.1111/1751-2980.12971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Uranga JA, Martínez V, Abalo R. Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use. Molecules 2020;25:E4314. [PMID: 32962285 DOI: 10.3390/molecules25184314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
5 Mohammadian G, Dlugosz A, Shetye J, Lindberg G. Quantification of mucosal EEC in jejunum. A comparative study of IBS patients and healthy controls. Scand J Gastroenterol 2020;55:543-8. [PMID: 32442056 DOI: 10.1080/00365521.2020.1764615] [Reference Citation Analysis]
6 López-gómez L, Bagüés A, Uranga JA, Abalo R. Preclinical models of irritable bowel syndrome. A Comprehensive Overview of Irritable Bowel Syndrome. Elsevier; 2020. pp. 233-76. [DOI: 10.1016/b978-0-12-821324-7.00012-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Vanner S, Lomax A, Jimenez-vargas NN. Neuroimmune Signaling in the Gastrointestinal Tract. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11079-7] [Reference Citation Analysis]
8 Tuck CJ, Caminero A, Jiménez Vargas NN, Soltys CL, Jaramillo Polanco JO, Lopez Lopez CD, Constante M, Lourenssen SR, Verdu EF, Muir JG, Lomax AE, Reed DE, Vanner SJ. The impact of dietary fermentable carbohydrates on a postinflammatory model of irritable bowel syndrome. Neurogastroenterol Motil 2019;31:e13675. [PMID: 31290223 DOI: 10.1111/nmo.13675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Lomax AE, Pradhananga S, Sessenwein JL, O'Malley D. Bacterial modulation of visceral sensation: mediators and mechanisms. Am J Physiol Gastrointest Liver Physiol 2019;317:G363-72. [PMID: 31290688 DOI: 10.1152/ajpgi.00052.2019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
10 Nasser Y, Petes C, Simmers C, Basso L, Altier C, Gee K, Vanner SJ. Activation of Peripheral Blood CD4+ T-Cells in IBS is not Associated with Gastrointestinal or Psychological Symptoms. Sci Rep 2019;9:3710. [PMID: 30842618 DOI: 10.1038/s41598-019-40124-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Tikoo S, Barki N, Jain R, Zulkhernain NS, Buhner S, Schemann M, Weninger W. Imaging of mast cells. Immunol Rev 2018;282:58-72. [PMID: 29431206 DOI: 10.1111/imr.12631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
12 Buhner S, Hahne H, Hartwig K, Li Q, Vignali S, Ostertag D, Meng C, Hörmannsperger G, Braak B, Pehl C, Frieling T, Barbara G, De Giorgio R, Demir IE, Ceyhan GO, Zeller F, Boeckxstaens G, Haller D, Kuster B, Schemann M. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One 2018;13:e0193943. [PMID: 29529042 DOI: 10.1371/journal.pone.0193943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
13 Chang L, Di Lorenzo C, Farrugia G, Hamilton FA, Mawe GM, Pasricha PJ, Wiley JW. Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. Gastroenterology 2018;154:723-35. [PMID: 29288656 DOI: 10.1053/j.gastro.2017.12.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
14 Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine 2017;99:132-8. [PMID: 28886490 DOI: 10.1016/j.cyto.2017.08.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
15 Martínez C, Rodiño-Janeiro BK, Lobo B, Stanifer ML, Klaus B, Granzow M, González-Castro AM, Salvo-Romero E, Alonso-Cotoner C, Pigrau M, Roeth R, Rappold G, Huber W, González-Silos R, Lorenzo J, de Torres I, Azpiroz F, Boulant S, Vicario M, Niesler B, Santos J. miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut 2017;66:1537-8. [PMID: 28082316 DOI: 10.1136/gutjnl-2016-311477] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
16 Boeckxstaens GE, Wouters MM. Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome. Neurogastroenterol Motil 2017;29. [PMID: 28027594 DOI: 10.1111/nmo.13007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
17 Reed DE, Vanner SJ. Emerging studies of human visceral nociceptors. Am J Physiol Gastrointest Liver Physiol 2017;312:G201-7. [PMID: 28007748 DOI: 10.1152/ajpgi.00391.2016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Ishimoto H, Oshima T, Sei H, Yamasaki T, Kondo T, Tozawa K, Tomita T, Ohda Y, Fukui H, Watari J, Miwa H. Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients. J Clin Biochem Nutr 2017;60:146-50. [PMID: 28366996 DOI: 10.3164/jcbn.16-92] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
19 Guarino MP, Barbara G, Cicenia A, Altomare A, Barbaro MR, Cocca S, Scirocco A, Cremon C, Emerenziani S, Stanghellini V, Cicala M, Severi C. Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. Neurogastroenterol Motil 2017;29. [PMID: 27619727 DOI: 10.1111/nmo.12928] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract. 2016;2016:2031480. [PMID: 28115927 DOI: 10.1155/2016/2031480] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
21 Guarino MPL, Cicala M, Putignani L, Severi C. Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World J Gastroenterol 2016; 22(45): 9871-9879 [PMID: 28018095 DOI: 10.3748/wjg.v22.i45.9871] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
22 Kwon YH, Kim HJ. [Current Status of Translational Research on Irritable Bowel Syndrome]. Korean J Gastroenterol 2016;68:138-42. [PMID: 27646582 DOI: 10.4166/kjg.2016.68.3.138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Vergnolle N. Protease inhibition as new therapeutic strategy for GI diseases. Gut 2016;65:1215-24. [PMID: 27196587 DOI: 10.1136/gutjnl-2015-309147] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 18.1] [Reference Citation Analysis]
24 Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. [PMID: 27159638 DOI: 10.1038/nrdp.2016.14] [Cited by in Crossref: 483] [Cited by in F6Publishing: 495] [Article Influence: 69.0] [Reference Citation Analysis]
25 Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, Rossi F, Lo Monte AI, Rizzo AG, Raimondo D. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol 2016; 22(7): 2242-2255 [PMID: 26900287 DOI: 10.3748/wjg.v22.i7.2242] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
26 Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, Vergnolle N, Zoetendal EG. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology 2016:S0016-5085(16)00219-5. [PMID: 27144620 DOI: 10.1053/j.gastro.2016.02.028] [Cited by in Crossref: 186] [Cited by in F6Publishing: 192] [Article Influence: 26.6] [Reference Citation Analysis]
27 Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut 2016;65:155-68. [PMID: 26194403 DOI: 10.1136/gutjnl-2015-309151] [Cited by in Crossref: 199] [Cited by in F6Publishing: 168] [Article Influence: 28.4] [Reference Citation Analysis]
28 Campaniello MA, Harrington AM, Martin CM, Ashley Blackshaw L, Brierley SM, Hughes PA. Activation of colo-rectal high-threshold afferent nerves by Interleukin-2 is tetrodotoxin-sensitive and upregulated in a mouse model of chronic visceral hypersensitivity. Neurogastroenterol Motil 2016;28:54-63. [PMID: 26468044 DOI: 10.1111/nmo.12696] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ostertag D, Buhner S, Michel K, Pehl C, Kurjak M, Götzberger M, Schulte-Frohlinde E, Frieling T, Enck P, Phillip J, Schemann M. Reduced Responses of Submucous Neurons from Irritable Bowel Syndrome Patients to a Cocktail Containing Histamine, Serotonin, TNFα, and Tryptase (IBS-Cocktail). Front Neurosci 2015;9:465. [PMID: 26733780 DOI: 10.3389/fnins.2015.00465] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
30 Elsenbruch S, Häuser W, Jänig W. Viszeraler Schmerz. Schmerz 2015;29:496-502. [DOI: 10.1007/s00482-015-0027-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
31 Hornby PJ. Drug discovery approaches to irritable bowel syndrome. Expert Opinion on Drug Discovery 2015;10:809-24. [DOI: 10.1517/17460441.2015.1049528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Cipriani G, Gibbons SJ, Saravanaperumal SA, Malysz J, Sha L, Szurszewski JH, Linden DR, Evangelista S, Faussone-Pellegrini MS, Vannucchi MG, Farrugia G. Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide. Neurogastroenterol Motil 2015;27:997-1009. [PMID: 25930994 DOI: 10.1111/nmo.12576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
33 Hungin AP, Becher A, Cayley B, Heidelbaugh JJ, Muris JW, Rubin G, Seifert B, Russell A, De Wit NJ. Irritable bowel syndrome: an integrated explanatory model for clinical practice. Neurogastroenterol Motil 2015;27:750-63. [PMID: 25703486 DOI: 10.1111/nmo.12524] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
34 Mawe GM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin Invest. 2015;125:949-955. [PMID: 25729851 DOI: 10.1172/jci76306] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 7.8] [Reference Citation Analysis]
35 Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49. [PMID: 25446728 DOI: 10.1038/nrgastro.2014.200] [Cited by in Crossref: 128] [Cited by in F6Publishing: 105] [Article Influence: 16.0] [Reference Citation Analysis]
36 Camilleri M. Novel therapeutic agents in neurogastroenterology: advances in the past year. Neurogastroenterol Motil 2014;26:1070-8. [PMID: 24953086 DOI: 10.1111/nmo.12386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]